Predictive Oncology Inc. is at the forefront of revolutionizing medicine through AI-driven biomarker and drug discovery for precision health. With a vast biobank of diverse live-cell tumor specimens, the company is uniquely positioned to drive long-term value and shape the future of cancer treatment and drug development. Collaborating with UPMC Magee-Womens Hospital, Predictive Oncology developed AI-powered multi-omic machine learning models that outperform traditional clinical data-based models in predicting survival outcomes for ovarian cancer patients. These breakthrough models not only enhance early drug discovery but also have the potential to personalize treatments and improve patient outcomes, particularly in challenging cancers like high-grade serous ovarian cancer. The company is actively refining these models for integration into clinical practice at leading cancer centers worldwide, ushering in a new era of personalized cancer care.The success of Predictive Oncology’s biomarker discovery efforts in ovarian cancer has paved the way for identifying novel biomarkers linked to patient survival and drug response across various tumor types. This transformative opportunity in the AI platform aligns with the growing biomarker discovery market, projected to reach $14.5 billion by 2030. By leveraging partnerships with biopharmaceutical companies and healthcare networks, Predictive Oncology aims to capitalize on this momentum and drive further innovation in precision medicine. Additionally, the company’s focus on enhancing drug discovery success through early-stage validation of AI drug response predictions with real-world tumor samples offers a strategic advantage in reducing clinical trial failure rates and optimizing R&D investments. Furthermore, Predictive Oncology’s capability to repurpose abandoned oncology drugs using active machine learning presents a unique value proposition, unlocking the potential of shelved compounds and efficiently transitioning them back into clinical readiness for the benefit of patients and drug developers.
Read more from menafn.com
